India’s leading drugmakers are shifting focus from US generics to domestic sales, emerging markets, and innovative therapies, signalling a strategic industry transformation driven by US market pressures and international growth opportunities.
India’s biggest pharmaceutical companies are leaning more heavily on domestic sales, emerging markets and newer therapies to offset a softer US generics backdrop, according to an analysis of first-quarter results from Sun Pharmaceutical Industries, Aurobindo Pharma and Dr Reddy’s Laboratories. The pattern reflects a broader industry shift: Indian drugmakers are using their home market, export diversification and a growing portfolio of more specialised products to reduce reliance on commoditised medicines in America.
Sun Pharma remained the largest of the three and delivered the clearest proof of that pivot. Revenue rose 10% year on year to ₹15,184 crore in the quarter, helped by a 16% rise in India formulations to ₹5,475 crore and a 12.8% increase in global innovative medicines sales to $351 million. Emerging-market revenue also edged up 4.2% to $311 million, even as US formulations fell 9.7% to $427 million. The company’s innovative medicines business accounted for 21.9% of total sales, underlining the significance of higher-value products in its mix. Sun’s EBITDA rose more slowly, while margins narrowed, but reported profit still increased.
Aurobindo Pharma posted the fastest growth among the three, with revenue up 16.3% to ₹9,150 crore and net profit climbing 25% to ₹1,032 crore. EBITDA rose 20% to ₹1,924 crore and margins improved modestly to 21%. The result suggests the company is benefiting from a broader product base and a more balanced geographic profile at a time when US pricing pressure continues to weigh on generic producers.
Dr Reddy’s Laboratories, by contrast, showed how exposed even diversified players can remain when a single market or product line weakens. Revenue fell 5.6% to ₹8,071 crore and profit attributable to shareholders dropped 69% to ₹444 crore, as North America sales declined 35% to ₹2,205 crore. The fall was driven largely by lower lenalidomide sales, while the company also booked a ₹240 crore provision tied to semaglutide API, cutting margins by about three percentage points. Even so, the Hyderabad-based group saw emerging markets rise 31%, India 17% and Europe 13%, pointing to progress in areas beyond the US.
Industry research suggests this rebalancing is not temporary. Reports on India’s pharmaceutical sector estimate a market size of about $60 billion in FY26, with domestic branded generics providing a steady, high-margin base and contract development and manufacturing, or CDMO, gaining traction as global companies seek supply chains that are less dependent on China. India Briefing and other sector analyses say exports of critical drugs have also strengthened in 2026, helped by demand for generic medicines, oncology treatments, vaccines and specialty pharmaceuticals. Together, the latest quarterly numbers and wider industry data show Indian drugmakers moving further away from a pure US generics story and towards a more diversified model built on branded products, innovative medicines and wider international reach.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
